72 research outputs found
Explosive Nucleosynthesis: What we learned and what we still do not understand
This review touches on historical aspects, going back to the early days of
nuclear astrophysics, initiated by BFH and Cameron, discusses (i) the
required nuclear input from reaction rates and decay properties up to the
nuclear equation of state, continues (ii) with the tools to perform
nucleosynthesis calculations and (iii) early parametrized nucleosynthesis
studies, before (iv) reliable stellar models became available for the late
stages of stellar evolution. It passes then through (v) explosive environments
from core-collapse supernovae to explosive events in binary systems (including
type Ia supernovae and compact binary mergers), and finally (vi) discusses the
role of all these nucleosynthesis production sites in the evolution of
galaxies. The focus is put on the comparison of early ideas and present, very
recent, understanding.Comment: 11 pages, to appear in Springer Proceedings in Physics (Proc. of
Intl. Conf. "Nuclei in the Cosmos XV", LNGS Assergi, Italy, June 2018
Perinatal Asphyxia Affects Rat Auditory Processing: Implications for Auditory Perceptual Impairments in Neurodevelopmental Disorders
Perinatal asphyxia, a naturally and commonly occurring risk factor in birthing, represents one of the major causes of neonatal encephalopathy with long term consequences for infants. Here, degraded spectral and temporal responses to sounds were recorded from neurons in the primary auditory cortex (A1) of adult rats exposed to asphyxia at birth. Response onset latencies and durations were increased. Response amplitudes were reduced. Tuning curves were broader. Degraded successive-stimulus masking inhibitory mechanisms were associated with a reduced capability of neurons to follow higher-rate repetitive stimuli. The architecture of peripheral inner ear sensory epithelium was preserved, suggesting that recorded abnormalities can be of central origin. Some implications of these findings for the genesis of language perception deficits or for impaired language expression recorded in developmental disorders, such as autism spectrum disorders, contributed to by perinatal asphyxia, are discussed
Liver cell therapy: is this the end of the beginning?
The prevalence of liver diseases is increasing globally. Orthotopic liver transplantation is widely used to treat liver disease upon organ failure. The complexity of this procedure and finite numbers of healthy organ donors have prompted research into alternative therapeutic options to treat liver disease. This includes the transplantation of liver cells to promote regeneration. While successful, the routine supply of good quality human liver cells is limited. Therefore, renewable and scalable sources of these cells are sought. Liver progenitor and pluripotent stem cells offer potential cell sources that could be used clinically. This review discusses recent approaches in liver cell transplantation and requirements to improve the process, with the ultimate goal being efficient organ regeneration. We also discuss the potential off-target effects of cell-based therapies, and the advantages and drawbacks of current pre-clinical animal models used to study organ senescence, repopulation and regeneration
Lawson criterion for ignition exceeded in an inertial fusion experiment
For more than half a century, researchers around the world have been engaged in attempts to achieve fusion ignition as a proof of principle of various fusion concepts. Following the Lawson criterion, an ignited plasma is one where the fusion heating power is high enough to overcome all the physical processes that cool the fusion plasma, creating a positive thermodynamic feedback loop with rapidly increasing temperature. In inertially confined fusion, ignition is a state where the fusion plasma can begin "burn propagation" into surrounding cold fuel, enabling the possibility of high energy gain. While "scientific breakeven" (i.e., unity target gain) has not yet been achieved (here target gain is 0.72, 1.37Â MJ of fusion for 1.92Â MJ of laser energy), this Letter reports the first controlled fusion experiment, using laser indirect drive, on the National Ignition Facility to produce capsule gain (here 5.8) and reach ignition by nine different formulations of the Lawson criterion
An Update on Pharmacological, Pharmacokinetic Properties and DrugâDrug Interactions of Rotigotine Transdermal System in Parkinsonâs Disease and Restless Legs Syndrome
Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch
<p>Abstract</p> <p>Background</p> <p>Rotigotine is a unique dopamine agonist with activity across D1 through D5 receptors as well as select adrenergic and serotonergic sites. This study reports the 2-year follow-up safety and efficacy data of an ongoing open-label multicenter extension study (NCT00498186) of transdermal rotigotine in patients with moderate to severe restless legs syndrome (RLS).</p> <p>Methods</p> <p>Patients received a once-daily patch application of an individually optimized dose of rotigotine between 0.5 mg/24 h to 4 mg/24 h. Safety assessments included adverse events (AEs) and efficacy was measured by the International RLS Study Group Severity Rating Scale (IRLS), RLS-6 scales and Clinical Global Impression (CGI). Quality of life (QoL) was measured by QoL-RLS.</p> <p>Results</p> <p>Of 310 patients who completed a 6-week placebo-controlled trial (SP709), 295 (mean age 58 ± 10 years, 66% females) were included in the open-label trial SP710. 64.7% (190/295 patients) completed the 2-year follow-up; 29 patients discontinued during the second year. Mean daily rotigotine dose after 2 years was 2.93 ± 1.14 mg/24 h with a 2.9% dose increase from year 1. Rotigotine was generally well tolerated. The rate of typical dopaminergic side effects, nausea and fatigue, was low (0.9% and 2.3%, respectively) during the second year; application site reactions were frequent but lower than in year 1 (16.4% vs. 34.5%). The IRLS total score improved from baseline of SP709 (27.8 ± 5.9) by 17.2 ± 9.2 in year 2 completers. Similar improvements were observed in RLS-6 scales, CGI scores and QoL-RLS. The responder rate in the CGI change item 2 ("much" and "very much" improved) was 95% after year 2.</p> <p>Conclusions</p> <p>Transdermal rotigotine is an efficacious and well-tolerated long-term treatment option for patients with moderate to severe RLS with a high retention rate during 2 years of therapy.</p> <p>Trial registration</p> <p>NCT00498186</p
Modern neuroimaging in psychiatry: Towards the integration of functional and molecular information
Thirty-five years of psychiatric imaging along traditional diagnostic boundaries have revealed a great deal about the structural and functional brain changes that accompany mental disorders but not produced reliable biomarkers. One reason may be that clinical syndromes represent the phenotypic expression of many different genotypes and biological pathways. Neuroimaging is now increasingly being used to map out the pathways from genes (obtained from candidate or genome-wide association studies) to the cognitive, emotional and behavioural phenotypes that result in syndromes like schizophrenia or depression. The armamentarium of neuroimaging is becoming increasingly versatile, and now includes methods with considerable spatial, temporal and/or molecular resolution. We can expect that a sophisticated combination of these techniques with genetic and pharmacological information will usher into a new era of psychiatric imaging that will aid a biological classification of mental diseases
Rotigotine transdermal patch: a guide to its use in Parkinsonâs disease and restless leg syndrome
The use of hyperventilation therapy after traumatic brain injury in Europe: an analysis of the BrainIT database
- âŠ